Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endocyte Inc announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival


Friday, 21 Mar 2014 08:09am EDT 

Endocyte Inc:Results from Phase 2b TARGET trial, which showed that study met primary endpoint for combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients.As randomized Phase 2b study, pre-defined statistical threshold for significance was a p-value of < 0.10 (one-sided test).The data showed that risk of disease worsening or death was reduced by 25 percent for patients treated with the vintafolide/docetaxel combination versus docetaxel alone (PFS HR 0.75, p-value 0.0696, one-sided test).Detailed trial results, including data regarding overall survival (OS), will be presented at an upcoming medical conference. 

Company Quote

6.2
-0.06 -0.96%
22 May 2015